Predicting COVID-19 outcomes in patients at advanced stages of HIV infection: a model-based approach
Open Access
- 1 March 2024
- journal article
- research article
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 29 (1) , 5-17
Abstract
BACKGROUND: Today, clinicians and their decisions extensively rely on specific treatment algorithms. These algorithms include prognostic models to identify high risk patients requiring hospital admission and clinical monitoring. This study suggests a prognostic model for forecasting COVID-19 outcomes in patients with advanced HIV infection, considering the high risk of unfavorable outcomes and the need for a specialized approach. AIM: To develop a prognostic model that combines predictors of unfavorable COVID-19 outcomes in patients with advanced HIV infection. MATERIALS AND METHODS: The study was based on 500 medical records of patients with advanced HIV infection admitted for confirmed COVID-19 between March 1, 2020, and December 31, 2022, and inpatient treatment at the Infectious Diseases Hospital in Moscow. RESULTS: All 500 patients were evaluated for 167 predictive markers for unfavorable COVID-19 outcomes, outlining 50 indicators that significantly varied across the subgroups of patients with both advanced HIV infection and COVID-19 depending on the presence of favorable or poor outcomes. Oxygen therapy was the most significant factor showing a strong correlation with poor outcomes in patients with advanced HIV infection and COVID-19. Subsequently, predictors were selected stepwise to enhance the predictive accuracy of the resulting model by adding more factors. The resulting model included seven factors: oxygen therapy requirements, CD4+ count under 50 cells/μL; manifested CMV infection with lung damage; elevated levels of lactate dehydrogenase, urea, and fibrinogen; and the presence of unspecified encephalitis. Using the available data in the calculations, a prognostic scenario and a receiver operating characteristic (ROC) curve were created to assess the practical significance of the proposed prognostic model. The area under the ROC curve was 90.9%, confirming the prediction accuracy and overall practical significance of the model. CONCLUSIONS: The proposed prognostic model enables the assessment of potential outcomes and planning of adequate therapies in patients with HIV and COVID-19 co-infection admitted to hospitals at advanced stages of the disease.Keywords
This publication has 15 references indexed in Scilit:
- Antiretroviral therapy-naïve people living with HIV tend to have more severe symptoms of COVID-19Chinese Medical Journal, 2023
- COVID‐19 among adults living with HIV: correlates of mortality among public sector healthcare users in Western Cape, South AfricaJournal of the International AIDS Society, 2023
- Clinical Features and Outcomes of Coronavirus Disease 2019 Among People With Human Immunodeficiency Virus in the United States: A Multicenter Study From a Large Global Health Research Network (TriNetX)Open Forum Infectious Diseases, 2021
- Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational StudyClinical Infectious Diseases, 2020
- Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019Clinical Infectious Diseases, 2020
- Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysisJournal of Infection, 2020
- Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in ChinaChest, 2020
- Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisalBMJ, 2020
- Lactate dehydrogenase is associated with 28-day mortality in patients with sepsis: a retrospective observational studyJournal of Surgical Research, 2018
- Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancerBritish Journal of Cancer, 2017